Lineage Cell Therapeutics: Q4 Earnings Insights

Lineage Cell Therapeutics LCTX reported its Q4 earnings results on Thursday, March 7, 2024 at 04:01 PM.

Here's what investors need to know about the announcement.

Lineage Cell Therapeutics beat estimated earnings by 25.0%, reporting an EPS of $-0.03 versus an estimate of $-0.04.

Revenue was up $200 thousand from the same period last year.

Last quarter the company missed on EPS by $0.0 which was followed by a 3.0% drop in the share price the next day.

Here's a look at Lineage Cell Therapeutics's past performance:

Quarter	Q3 2023	Q2 2023	Q1 2023	Q4 2022
EPS Estimate	-0.04	-0.04	-0.04	-0.04
EPS Actual	-0.04	-0.03	-0.03	-0.03
Revenue Estimate	2.59M	2.20M	2.01M	2.57M
Revenue Actual	1.25M	3.23M	2.39M	1.90M

To track all earnings releases for Lineage Cell Therapeutics visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Calendar